Pharmaceutical Technology Europe-04-01-2009

Pharmaceutical Technology Europe

The number of biotechnology-based human therapeutic products in the late-stage pipeline along with the average cost to commercialize a biotech product has been steadily increasing with time. In addition, the biotech industry is facing unprecedented challenges of a sagging global economy and rising regulatory expectations. Companies have to continue to evolve their approaches to be more efficient with respect to time, resources and cost. This article describes some of the technologies that can help optimize time and cost of biopharmaecutical manufacturing.

Pharmaceutical Technology Europe
Outsourcing review

April 01, 2009

Despite the market downturn and financial meltdown, private equity investors are lining up for pharmaceutical services businesses.

Pharmaceutical Technology Europe
PAT

April 01, 2009

Operational excellence awaits, but only if you can implement PAT successfully.

Pharmaceutical Technology Europe
Analytical

April 01, 2009

An expert on diffraction systems offers insight on particle size specifications and analysis.

Pharmaceutical Technology Europe

April 01, 2009

The formation of a partnership, whether personal or professional, is risky business.

Pharmaceutical Technology Europe

Even small amounts of amorphous materials can have a significant effect on the drug product. Are gravimetric vapour sorption techniques an effective solution to characterize amorphous materials?

Pharmaceutical Technology Europe

Steps companies can take to help safeguard patients and the pharma supply chain.